Erespal 80mg N30 coated pills
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Fenspirid
Release form
Pills
Composition
Active ingredient: Fenspiride (Fenspiride) Active ingredient concentration (mg): 80
Pharmacological effect
Anti-inflammatory and anti-bronchoconstrictor activity of fenspiride is due to a decrease in the production of a number of biologically active substances (cytokines (especially phno α), arachidonic acid derivatives, free radicals), which play an important role in the development of inflammation and bronchospasm. to. Histamine stimulates the metabolism of arachidonic acid to form prostaglandins and leukotrienes. Fenspiride blocks α-adrenoreceptors, stimulation of which is accompanied by an increase in the secretion of bronchial glands. Thus, fenspirid reduces the effect of a number of factors that contribute to the hypersecretion of proinflammatory factors, the development of inflammation and bronchial obstruction. Fenspirid also has an antispasmodic effect.
Pharmacokinetics
After ingestion, Cmax is reached after 6 hours. Excretion of T1 / 2 is 12 hours. Excreted mainly by the kidneys.
Indications
Diseases of the upper and lower respiratory tract: nasopharyngitis and laryngitis; tracheobronchitis; bronchitis (with or without chronic respiratory failure); bronchial asthma (as part of complex therapy); respiratory phenomena (cough, hoarseness, sore throat) for measles, whooping cough, flu; infectious diseases of the respiratory tract, accompanied by cough, when shown standard antibiotic therapy. Otitis and sinusitis of various etiologies.
Contraindications
Children under 18 years of age (Erespal syrup should be used to treat children and adolescents under 18 years of age); Hypersensitivity to the active substance and / or any of the components of the drug.
Precautionary measures
The drug should be stored out of reach of children at a temperature not exceeding 25 ° C.
Use during pregnancy and lactation
Data on the use of the drug Erespal in pregnant women are missing or limited. The use of the drug during pregnancy is not recommended. Fenspiride therapy is not a reason to terminate the pregnancy. Erespal should not be used during breastfeeding due to the lack of data on the penetration of fenspiride into breast milk.
Dosage and administration
Adults are prescribed 80 mg (1 tab.) 2-3 times / day. The maximum daily dose is 240 mg.The duration of treatment is determined by the doctor.
Side effects
The patient should be informed about the need to inform the doctor about any, including undesirable reactions not mentioned above, as well as changes in laboratory parameters during therapy with Erespal. The most frequent adverse reactions to Erespal are observed on the part of the digestive system. The frequency of adverse reactions that may occur during therapy is given as follows: very often (more than 1/10); often (more than 1/100, less than 1/10); infrequently (more than 1/1000, less than 1/100); rarely (more than 1/10 000, less than 1/1000); very rarely (less than 1/10 000); Unspecified frequency (frequency cannot be calculated from available data). From the cardiovascular system: rarely - moderate tachycardia, the severity of which decreases with decreasing the dose of the drug; unspecified frequency * - palpitations and a decrease in blood pressure, possibly associated with tachycardia. On the digestive system: often - gastrointestinal disorders, nausea, epigastric pain; Unspecified frequency * - diarrhea, vomiting. CNS: rarely - drowsiness; unspecified frequency * - dizziness. From the side of the skin and subcutaneous fat: rarely - erythema, rash, urticaria, angioedema, fixed pigment erythema; Unspecified frequency * - pruritus, toxic epidermal necrolysis, Stevens-Johnson syndrome. General disorders: Unspecified frequency * - asthenia, increased fatigue. * Data of post-registration use.
Overdose
In case of overdose (overdose cases are noted when taking the drug in a dose of more than 2320 mg), the patient should immediately seek medical help. Symptoms: drowsiness or agitation, nausea, vomiting, sinus tachycardia. Treatment: gastric lavage, ECG monitoring, maintenance of vital body functions .
Interaction with other drugs
Special studies on the interaction of fenspiride with other drugs have not been carried out. Because of the possible sedative effect when taking histamine H1 receptor blockers, the use of Erespal in combination with drugs that have a sedative effect, or together with alcohol is not recommended.
special instructions
For the treatment of children and adolescents under the age of 18, Erespal syrup should be used. Impact on the ability to drive vehicles and control mechanisms Studies on the effect of the drug Erespal on the ability to drive vehicles and work with mechanisms have not been conducted. Patients should be aware of the possible development of drowsiness when taking the drug Erespal, especially at the beginning of therapy or when combined with alcohol, and should be careful when driving vehicles and when performing work that requires high speed psychomotor reactions.